{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:25:09Z","timestamp":1780723509987,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High-dose methotrexate (HD-MTX) is used in the treatment of different childhood cancers, including leukemia, the most common cancer type and is commonly defined as an intravenous dose of at least 1\u00a0g\/m<jats:sup>2<\/jats:sup> body surface area per application. A systematic review on late effects on different organs due to HD-MTX is lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We conducted a systematic literature search in PubMed, including studies published in English or German between 1985 and 2020. The population of each study had to consist of at least 75% childhood cancer survivors (CCSs) who had completed the cancer treatment at least twelve months before late effects were assessed and who had received HD-MTX. The literature search was not restricted to specific cancer diagnosis or organ systems at risk for late effects. We excluded case reports, case series, commentaries, editorial letters, poster abstracts, narrative reviews and studies only reporting prevalence of late effects. We followed PRISMA guidelines, assessed the quality of the eligible studies according to GRADE criteria and registered the protocol on PROSPERO (ID: CRD42020212262).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 15 out of 1731 identified studies. Most studies included CCSs diagnosed with acute lymphoblastic leukemia (<jats:italic>n<\/jats:italic>\u2009=\u200912). The included studies investigated late effects of HD-MTX on central nervous system (<jats:italic>n<\/jats:italic>\u2009=\u200910), renal (<jats:italic>n<\/jats:italic>\u2009=\u20092) and bone health (<jats:italic>n<\/jats:italic>\u2009=\u20093). Nine studies showed adverse outcomes in neuropsychological testing in exposed compared to non-exposed CCSs, healthy controls or reference values. No study revealed lower bone density or worse renal function in exposed CCSs. As a limitation, the overall quality of the studies per organ system was low to very low, mainly due to selection bias, missing adjustment for important confounders and low precision.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CCSs treated with HD-MTX might benefit from neuropsychological testing, to intervene early in case of abnormal results. Methodological shortcomings and heterogeneity of the tests used made it impossible to determine the most appropriate test. Based on the few studies on renal function and bone health, regular screening for dysfunction seems not to be justified. Only screening for neurocognitive late effects is warranted in CCSs treated with HD-MTX.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09145-0","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T09:03:13Z","timestamp":1647248593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Late effects of high-dose methotrexate treatment in childhood cancer survivors\u2014a systematic review"],"prefix":"10.1186","volume":"22","author":[{"given":"Eveline","family":"Daetwyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-502X","authenticated-orcid":false,"given":"Maria","family":"Otth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Scheinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"5","key":"9145_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3109\/0284186x.2015.1008648","volume":"54","author":"JF Winther","year":"2015","unstructured":"Winther JF, Kenborg L, Byrne J, Hjorth L, Kaatsch P, Kremer LC, et al. Childhood cancer survivor cohorts in Europe. Acta oncologica (Stockholm, Sweden). 2015;54(5):655\u201368. https:\/\/doi.org\/10.3109\/0284186x.2015.1008648.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"1","key":"9145_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","volume":"15","author":"G Gatta","year":"2014","unstructured":"Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2013a population-based study. Lancet Oncol. 2014;15(1):35\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(13)70548-5.","journal-title":"Lancet Oncol"},{"issue":"15","key":"9145_CR3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572\u201382. https:\/\/doi.org\/10.1056\/NEJMsa060185.","journal-title":"N Engl J Med"},{"issue":"24","key":"9145_CR4","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1001\/jama.297.24.2705","volume":"297","author":"MM Geenen","year":"2007","unstructured":"Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705\u201315. https:\/\/doi.org\/10.1001\/jama.297.24.2705.","journal-title":"JAMA"},{"key":"9145_CR5","volume-title":"Long Term Follow-Up guidelines Version 5.0","author":"Childrens Oncology Group","year":"2018","unstructured":"Childrens Oncology Group. Long Term Follow-Up guidelines Version 5.0. 2018. (http:\/\/www.survivorshipguidelines.orgAccessed 25.08.2020 (October 2018))."},{"key":"9145_CR6","volume-title":"Therapy based long term follow-up - Practice Statement","author":"United Kingdom Children\u2019s Cancer Study Group","year":"2005","unstructured":"United Kingdom Children\u2019s Cancer Study Group. Therapy based long term follow-up - Practice Statement. 2005."},{"key":"9145_CR7","volume-title":"Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis","author":"SKION DCOG","year":"2010","unstructured":"SKION DCOG. Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. 2010. (https:\/\/www.skion.nl\/voor-patienten-en-ouders\/late-effecten\/533\/richtlijn-follow-up-na-kinderkanker\/ Accessed 25.08.2020)."},{"issue":"1","key":"9145_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","volume":"62","author":"SL Cooper","year":"2015","unstructured":"Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61\u201373. https:\/\/doi.org\/10.1016\/j.pcl.2014.09.006.","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"9145_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.nurt.2009.04.006","volume":"6","author":"S Mueller","year":"2009","unstructured":"Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics\u202f: the journal of the American Society for Experimental NeuroTherapeutics. 2009;6(3):570\u201386. https:\/\/doi.org\/10.1016\/j.nurt.2009.04.006.","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"6","key":"9145_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11912-007-0064-6","volume":"9","author":"TG Gross","year":"2007","unstructured":"Gross TG, Termuhlen AM. Pediatric non-Hodgkin\u2019s lymphoma. Curr Oncol Rep. 2007;9(6):459\u201365. https:\/\/doi.org\/10.1007\/s11912-007-0064-6.","journal-title":"Curr Oncol Rep"},{"issue":"27","key":"9145_CR11","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/jco.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2015;33(27):3029\u201335. https:\/\/doi.org\/10.1200\/jco.2014.59.4895.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"9145_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.1987.5.12.2017","volume":"5","author":"SP Ackland","year":"1987","unstructured":"Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 1987;5(12):2017\u201331. https:\/\/doi.org\/10.1200\/jco.1987.5.12.2017.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"9145_CR13","unstructured":"Hall GW, S. Guidelines for use of HIGH DOSE METHOTREXATE (HDMTX). NHS. 2017. http:\/\/tvscn.nhs.uk\/wp-content\/uploads\/2014\/09\/Cancer-Children-High-Dose-Methotrexate-Guidance-for-Haematolgy-and-Oncology-v2.1-Dec-2015.pdf. Accessed 20.11.2021 2021."},{"key":"9145_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International journal of surgery (London, England). 2021;88: 105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"International journal of surgery (London, England)"},{"key":"9145_CR15","unstructured":"Scheinemann K, E; Otth, M; Drozdov, D; Bargetzi M. Late effect of high-dose methotrexate treatment in childhood cancer survivors - a systematic review. 2020. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020212262."},{"issue":"4","key":"9145_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/pbc.24445","volume":"60","author":"LC Kremer","year":"2013","unstructured":"Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60(4):543\u20139. https:\/\/doi.org\/10.1002\/pbc.24445.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"9145_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"9145_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00234-016-1777-8","volume":"59","author":"O Zaj\u0105c-Spycha\u0142a","year":"2017","unstructured":"Zaj\u0105c-Spycha\u0142a O, Pawlak MA, Karmelita-Katulska K, Pilarczyk J, Derwich K, Wachowiak J. Long-term brain structural magnetic resonance imaging and cognitive functioning in children treated for acute lymphoblastic leukemia with high-dose methotrexate chemotherapy alone or combined with CNS radiotherapy at reduced total dose to 12 Gy. Neuroradiology. 2017;59(2):147\u201356. https:\/\/doi.org\/10.1007\/s00234-016-1777-8.","journal-title":"Neuroradiology"},{"issue":"4","key":"9145_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/1573396314666181031134919","volume":"14","author":"LM Sherief","year":"2018","unstructured":"Sherief LM, Sanad R, ElHaddad A, Shebl A, Abdelkhalek ER, Elsafy ER, et al. A Cross-sectional Study of Two Chemotherapy Protocols on Long Term Neurocognitive Functions in Egyptian Children Surviving Acute Lymphoblastic Leukemia. Curr Pediatr Rev. 2018;14(4):253\u201360. https:\/\/doi.org\/10.2174\/1573396314666181031134919.","journal-title":"Curr Pediatr Rev"},{"key":"9145_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-8722-4-42","volume":"4","author":"C Halsey","year":"2011","unstructured":"Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4:42. https:\/\/doi.org\/10.1186\/1756-8722-4-42.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"9145_CR21","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/jco.2006.05.9055","volume":"24","author":"BJ Spiegler","year":"2006","unstructured":"Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2006;24(24):3858\u201364. https:\/\/doi.org\/10.1200\/jco.2006.05.9055.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"9145_CR22","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1080\/10428194.2018.1434879","volume":"59","author":"O Zaj\u0105c-Spycha\u0142a","year":"2018","unstructured":"Zaj\u0105c-Spycha\u0142a O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, Jo\u0144czyk-Potoczna K, Przepi\u00f3ra A, et al. Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. Leuk Lymphoma. 2018;59(10):2342\u201351. https:\/\/doi.org\/10.1080\/10428194.2018.1434879.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"9145_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaoncol.2015.4398","volume":"2","author":"MN Edelmann","year":"2016","unstructured":"Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, et al. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncol. 2016;2(2):201\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4398.","journal-title":"JAMA Oncol"},{"issue":"3","key":"9145_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11764-018-0679-7","volume":"12","author":"W Liu","year":"2018","unstructured":"Liu W, Cheung YT, Conklin HM, Jacola LM, Srivastava D, Nolan VG, et al. Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Journal of cancer survivorship\u202f: research and practice. 2018;12(3):398\u2013406. https:\/\/doi.org\/10.1007\/s11764-018-0679-7.","journal-title":"Journal of cancer survivorship : research and practice"},{"issue":"2","key":"9145_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/jnci\/djy089","volume":"111","author":"S Fellah","year":"2019","unstructured":"Fellah S, Cheung YT, Scoggins MA, Zou P, Sabin ND, Pui CH, et al. Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2019;111(2):201\u20139. https:\/\/doi.org\/10.1093\/jnci\/djy089.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"9145_CR26","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/jco.2007.12.4149","volume":"26","author":"NC Jansen","year":"2008","unstructured":"Jansen NC, Kingma A, Schuitema A, Bouma A, Veerman AJ, Kamps WA. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2008;26(18):3025\u201330. https:\/\/doi.org\/10.1200\/jco.2007.12.4149.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"11","key":"9145_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/jco.2015.64.3205","volume":"34","author":"LM Jacola","year":"2016","unstructured":"Jacola LM, Krull KR, Pui CH, Pei D, Cheng C, Reddick WE, et al. Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2016;34(11):1239\u201347. https:\/\/doi.org\/10.1200\/jco.2015.64.3205.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"9145_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/pbc.21650","volume":"51","author":"MH Gr\u00f6nroos","year":"2008","unstructured":"Gr\u00f6nroos MH, Jahnukainen T, M\u00f6tt\u00f6nen M, Perkki\u00f6 M, Irjala K, Salmi TT. Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer. 2008;51(4):535\u20139. https:\/\/doi.org\/10.1002\/pbc.21650.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"9145_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1055-9965.Epi-13-0036","volume":"22","author":"RL Mulder","year":"2013","unstructured":"Mulder RL, Knijnenburg SL, Geskus RB, van Dalen EC, van der Pal HJ, Koning CC, et al. Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer epidemiology, biomarkers & prevention\u202f: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(10):1736\u201346. https:\/\/doi.org\/10.1158\/1055-9965.Epi-13-0036.","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"2","key":"9145_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1385\/jcd:5:2:167","volume":"5","author":"MH Lequin","year":"2002","unstructured":"Lequin MH, van der Shuis IM, Van Rijn RR, Hop WC, van ven Huevel-Eibrink MM, MuinckKeizer-Schrama SM, et al. Bone mineral assessment with tibial ultrasonometry and dual-energy X-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood. J Clin Densitom. 2002;5(2):167\u201373. https:\/\/doi.org\/10.1385\/jcd:5:2:167.","journal-title":"J Clin Densitom"},{"issue":"6","key":"9145_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1359\/jbmr.2002.17.6.1073","volume":"17","author":"V Tillmann","year":"2002","unstructured":"Tillmann V, Darlington AS, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. Journal of bone and mineral research\u202f: the official journal of the American Society for Bone and Mineral Research. 2002;17(6):1073\u201380. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1073.","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"issue":"4","key":"9145_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/1096-911x(20001001)35:4<415::aid-mpo4>3.0.co;2-9","volume":"35","author":"IM van der Sluis","year":"2000","unstructured":"van der Sluis IM, van den Heuvel-Eibrink MM, H\u00e4hlen K, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol. 2000;35(4):415\u201320. https:\/\/doi.org\/10.1002\/1096-911x(20001001)35:4%3c415::aid-mpo4%3e3.0.co;2-9.","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"9145_CR33","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s2352-3026(16)30110-7","volume":"3","author":"YT Cheung","year":"2016","unstructured":"Cheung YT, Sabin ND, Reddick WE, Bhojwani D, Liu W, Brinkman TM, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. The Lancet Haematology. 2016;3(10):e456\u201366. https:\/\/doi.org\/10.1016\/s2352-3026(16)30110-7.","journal-title":"The Lancet Haematology"},{"issue":"4","key":"9145_CR34","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/jco.1998.16.4.1505","volume":"16","author":"R Surtees","year":"1998","unstructured":"Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 1998;16(4):1505\u201311. https:\/\/doi.org\/10.1200\/jco.1998.16.4.1505.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"9145_CR35","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1200\/jco.1997.15.8.2800","volume":"15","author":"CT Quinn","year":"1997","unstructured":"Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 1997;15(8):2800\u20136. https:\/\/doi.org\/10.1200\/jco.1997.15.8.2800.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"9145_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuropharm.2018.07.007","volume":"139","author":"J Wen","year":"2018","unstructured":"Wen J, Maxwell RR, Wolf AJ, Spira M, Gulinello ME, Cole PD. Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model. Neuropharmacology. 2018;139:76\u201384. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.07.007.","journal-title":"Neuropharmacology"},{"issue":"12","key":"9145_CR37","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist. 2016;21(12):1471\u201382. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164.","journal-title":"Oncologist"},{"issue":"3","key":"9145_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10408363.2018.1427041","volume":"55","author":"E den Bakker","year":"2018","unstructured":"den Bakker E, Gemke R, B\u00f6kenkamp A. Endogenous markers for kidney function in children: a review. Crit Rev Clin Lab Sci. 2018;55(3):163\u201383. https:\/\/doi.org\/10.1080\/10408363.2018.1427041.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"11","key":"9145_CR39","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.bbmt.2012.06.006","volume":"18","author":"BL Laskin","year":"2012","unstructured":"Laskin BL, Nehus E, Goebel J, Khoury JC, Davies SM, Jodele S. Cystatin C-estimated glomerular filtration rate in pediatric autologous hematopoietic stem cell transplantation. Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation. 2012;18(11):1745\u201352. https:\/\/doi.org\/10.1016\/j.bbmt.2012.06.006.","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"},{"issue":"3","key":"9145_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00467-012-2341-3","volume":"28","author":"EJ Nehus","year":"2013","unstructured":"Nehus EJ, Laskin BL, Kathman TI, Bissler JJ. Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury. Pediatric nephrology (Berlin, Germany). 2013;28(3):453\u201361. https:\/\/doi.org\/10.1007\/s00467-012-2341-3.","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"issue":"2","key":"9145_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00198-014-2878-z","volume":"26","author":"MA den Hoed","year":"2015","unstructured":"den Hoed MA, Klap BC, te Winkel ML, Pieters R, van Waas M, Neggers SJ, et al. Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer. Osteoporosis international\u202f: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015;26(2):521\u20139. https:\/\/doi.org\/10.1007\/s00198-014-2878-z.","journal-title":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"key":"9145_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/903097","volume":"2011","author":"C Fan","year":"2011","unstructured":"Fan C, Georgiou KR, King TJ, Xian CJ. Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children. J Biomed Biotechnol. 2011;2011: 903097. https:\/\/doi.org\/10.1155\/2011\/903097.","journal-title":"J Biomed Biotechnol"},{"issue":"11","key":"9145_CR43","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1002\/cncr.23912","volume":"113","author":"IH Thomas","year":"2008","unstructured":"Thomas IH, Donohue JE, Ness KK, Dengel DR, Baker KS, Gurney JG. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer. 2008;113(11):3248\u201356. https:\/\/doi.org\/10.1002\/cncr.23912.","journal-title":"Cancer"},{"key":"9145_CR44","doi-asserted-by":"publisher","unstructured":"Limond JT, S; Bull, KS; Calaminus, G; Lemiere, J; Traunwieser, T; van Santen, HM, Weiler, L; Spoudeas, HA; Chevignard, M. Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years. Eur J Paediatr Neurol. 2020(25):59\u201367.\u00a0https:\/\/doi.org\/10.1016\/j.ejpn.2019.10.002.","DOI":"10.1016\/j.ejpn.2019.10.002"},{"key":"9145_CR45","doi-asserted-by":"publisher","unstructured":"Jacola LP, M; Lemiere, J; Hudson, MH; Thomas S. Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021(39(16)):1696\u2013704.\u00a0https:\/\/doi.org\/10.1200\/JCO.20.02444.","DOI":"10.1200\/JCO.20.02444"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T09:04:13Z","timestamp":1647248653000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9145"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09145-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for systematic review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for systematic review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}